All Stories

  1. Donor anti-cytomegalovirus IgG titer and risk of cytomegalovirus infection after D+R- kidney transplantation, results from the TransplantLines Biobank and Cohort Study
  2. Triglyceride-rich lipoprotein cholesterol is elevated in liver transplant recipients and associated with post-transplant diabetes
  3. Computational assessment of memory function in kidney transplant recipients and donors
  4. Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study
  5. Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial
  6. Relevance of Epstein-Barr Virus (EBV) miRNAs in EBV-Infected B Cells and B-Cell Lymphomas
  7. Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study
  8. Non-Invasive Detection of Acute Kidney Allograft Rejection Using [18F]FB-IL2 PET-CT: A First in Human Proof-of-Concept Study
  9. Intra-erythrocyte creatine, plasma creatine and long-term outcomes in stable kidney transplant recipients: Results from the TransplantLines Biobank and Cohort study
  10. Symptom Burden and Patient-Reported Outcomes in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Studies
  11. Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients
  12. Overlapping macrophage immune profiles in polymyalgia rheumatica and giant cell arteritis
  13. Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study
  14. Posttransplant Dynamics of Serum T50 and Coronary Artery Calcium Scores Among Kidney Transplant Recipients
  15. Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  16. Plasma creatine, estimated intramuscular creatine and risk of mortality in stable kidney transplant recipients: Results from the TransplantLines biobank and cohort study
  17. Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma
  18. Urinary endotrophin as a biomarker for T cell–mediated rejection-associated fibrogenesis in kidney transplant recipients
  19. Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma
  20. Programmed cell death‐1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma
  21. Multi-Cohort High-Dimensional Proteomics Reveals Early Risk Markers for Lymphoid Cancer Subtypes
  22. Serum TARC dynamics during anti‐PD1‐based first‐line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial
  23. Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP
  24. IgM Immunohistochemical Expression is a Potential Risk Factor for Extracutaneous Dissemination in Patients With Primary Cutaneous Follicle Center Lymphoma
  25. MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis
  26. GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica
  27. Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment
  28. Insights in Cellular and Molecular Signatures of the Small Intestinal Graft Posttransplantation: Successful, Recovered, and Rejected—A Case Series
  29. Plasma trimethylamine N-oxide concentration and all-cause mortality in kidney transplant recipients
  30. Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics
  31. Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma
  32. Muscle Mass, Muscle Strength, and Health-Related Quality of Life in Kidney Transplant Recipients
  33. Validity of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) tool in a Dutch cohort of transplant recipients
  34. Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
  35. Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology
  36. The immune pathology of bursitis in rheumatic inflammatory diseases, degenerative conditions and mechanical stress: A systematic review
  37. ELISA-4-amyloid: diagnostic accuracy of an ELISA panel for typing the four main types of systemic amyloidosis in subcutaneous abdominal fat tissue samples
  38. Calciprotein particle counts associate with vascular remodelling in chronic kidney disease
  39. Iron deficiency, anemia, and patient-reported outcomes in kidney transplant recipients
  40. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry
  41. Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen
  42. Plasma symmetric dimethylarginine and kidney graft function in kidney transplant recipients
  43. Memory B-cell derived donor-specific antibodies do not predict outcome in sensitized kidney transplant recipients: a retrospective single-center study
  44. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
  45. Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis
  46. Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms
  47. TOX as a new diagnostic marker for T cell large granular lymphocytic leukaemia
  48. Health-related quality of life is linked to the gut microbiome in kidney transplant recipients
  49. Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years
  50. R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study
  51. Inhibition of the glutamate-cysteine ligase catalytic subunit with buthionine sulfoximine enhances the cytotoxic effect of doxorubicin and cyclophosphamide in Burkitt lymphoma cells
  52. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
  53. The Impact of Genetic Subtypes of Diffuse Large B-Cell Lymphoma for Outcome Prediction and Interpretation of FDG-PET treatment Response Monitoring
  54. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas
  55. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
  56. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
  57. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes
  58. A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
  59. Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controls
  60. Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study
  61. Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort study
  62. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
  63. Heparin-resistance in AL amyloidosis: a case report
  64. Long non‐coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B‐cell lymphoma
  65. M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism
  66. Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica
  67. The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics
  68. Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
  69. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis
  70. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
  71. Classification of Amyloidosis SubTypes by Synchrotron InfraRed MicroSpectroscopy
  72. T027: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
  73. Hand dexterity, daily functioning and health-related quality of life in kidney transplant recipients
  74. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica
  75. The lncRNA KTN1-AS1 co-regulates a variety of Myc-target genes and enhances proliferation of Burkitt lymphoma cells
  76. Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals
  77. Renal Endothelial Cytotoxicity Assay to Diagnose and Monitor Renal Transplant Recipients for Anti-Endothelial Antibodies
  78. Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer
  79. Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney
  80. Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach
  81. Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma
  82. Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome
  83. A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma
  84. CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2
  85. Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma
  86. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas
  87. Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing
  88. Plasma Lead Concentration and Risk of Late Kidney Allograft Failure: Findings From the TransplantLines Biobank and Cohort Studies
  89. HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients
  90. Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment
  91. Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome
  92. Boron Intake and decreased risk of mortality in kidney transplant recipients
  93. Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL)
  94. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
  95. Aggravation of fibrin deposition and microthrombus formation within the graft during kidney transplantation
  96. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
  97. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype
  98. Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality
  99. A Rare Case of Epstein-Barr Virus–Positive T-Cell Lymphoma in the Skin of an Immunocompromised Patient
  100. Case report of a clinically indolent but morphologically high‐grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?
  101. Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing
  102. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
  103. Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
  104. Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
  105. Genetically Raised Circulating Bilirubin Levels and Risk of Ten Cancers: A Mendelian Randomization Study
  106. Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development
  107. Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [18F]FDG PET/CT
  108. Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
  109. Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis
  110. Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58
  111. Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-Hoc Analysis of the MECANO Trial
  112. Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study
  113. Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy
  114. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
  115. Cell-free DNA as biomarker in Hodgkin lymphoma patients
  116. Interim thymus and activation regulated chemokine versus interim 18F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
  117. 18F-FDG PET/CT in the Diagnostic and Treatment Evaluation of Pediatric Posttransplant Lymphoproliferative Disorders
  118. Microenvironment, Cross-Talk, and Immune Escape Mechanisms
  119. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
  120. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial
  121. Complement activation and long-term graft function in ABO-incompatible kidney transplantation
  122. CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients
  123. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield
  124. Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
  125. Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
  126. Correction
  127. Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis
  128. Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
  129. Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
  130. Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones
  131. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
  132. Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment
  133. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma
  134. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation
  135. Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells
  136. The Microenvironment in Epstein–Barr Virus-Associated Malignancies
  137. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform
  138. Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries
  139. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
  140. Combined loss of HLA I and HLA II expression is more common in the non‐GCB type of diffuse large B cell lymphoma
  141. Erratum: The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor
  142. Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127
  143. Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma
  144. MicroRNA High Throughput Loss-of-Function Screening Reveals an Oncogenic Role for miR-21-5p in Hodgkin Lymphoma
  145. MYC Rearrangement Positive Large B-Cell Lymphoma Patients Can Be Treated Successfully with R-CHOP Plus Lenalidomide: Results of a Multicentre Phase II HOVON Trial
  146. Emerging roles for long noncoding RNAs in B-cell development and malignancy
  147. Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
  148. Relapse in stage I(E) diffuse large B-cell lymphoma
  149. Human alternative Klotho mRNA is a nonsense-mediated mRNA decay target inefficiently spliced in renal disease
  150. Targeting the Microenvironment in Hodgkin Lymphoma: Opportunities and Challenges
  151. Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome
  152. High human cytomegalovirus DNAemia early post-transplantation associates with irreversible and progressive loss of renal function - a retrospective study
  153. A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients
  154. miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis
  155. Kidney Involvement in Systemic Calcitonin Amyloidosis Associated With Medullary Thyroid Carcinoma
  156. ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma
  157. HLA expression and HLA type associations in relation to EBV status in Hispanic Hodgkin lymphoma patients
  158. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
  159. Human Cytomegalovirus-Encoded Receptor US28 Is Expressed in Renal Allografts and Facilitates Viral Spreading In Vitro
  160. Novel treatment concepts in Hodgkin lymphoma
  161. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
  162. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin‐1, sCD163 and sCD30 with TARC
  163. Progression of a solitary plasmacytoma to multiple myeloma. A population‐based registry of the northern Netherlands
  164. Long Noncoding RNA Expression Profiling in Normal B-Cell Subsets and Hodgkin Lymphoma Reveals Hodgkin and Reed-Sternberg Cell–Specific Long Noncoding RNAs
  165. CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse
  166. Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia
  167. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity
  168. The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein–Barr virus presence and location within the tumor
  169. Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas
  170. Mutations in CD58 and Other Immune System Related Genes in Hodgkin Lymphoma
  171. Mir-155 Enhances B-Cell Lymphoma Growth By Targeting TBRG1
  172. Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma
  173. A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma
  174. CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma
  175. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
  176. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: aHaemophilus influenzae-driven immune disorder?
  177. Long noncoding RNAs as a novel component of the Myc transcriptional network
  178. Microenvironment, Crosstalk, and Immune Escape Mechanisms
  179. Genetic Associations in Classical Hodgkin Lymphoma: A Systematic Review and Insights into Susceptibility Mechanisms
  180. Epstein–Barr virus, the germinal centre and the development of Hodgkin’s lymphoma
  181. Toll-like receptors in the pathogenesis of human B cell malignancies
  182. The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing
  183. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus
  184. The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component
  185. Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma
  186. The renal angiopoietin/Tie2 system in lethal human sepsis
  187. Specific PML Isoforms and SATB1 Affect HLA Expression In Classical Hodgkin Lymphoma
  188. The Role of MicroRNAs in Hodgkin's Lymphoma
  189. PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV+ Hodgkin Lymphoma
  190. A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis
  191. Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.
  192. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
  193. HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
  194. Huang X, Kushekhar K, Nolte I, Kooistra W, Visser L, Bouwman I, Kouprie N, Veenstra R, van Imhoff G, Olver B, Houlston RS, Poppema S, Diepstra A, Hepkema B, van den Berg A. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV ...
  195. HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
  196. Lithium induces intestinothrophic effects in the healthy colon, but does not ameliorate dextran sulfate sodium-induced colitis in mice
  197. Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined Subgroups
  198. Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma
  199. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups
  200. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma
  201. MiR‐17/106b seed family regulates p21 in Hodgkin's lymphoma
  202. Epidemiology of Classical Hodgkin Lymphoma and Its Association with Epstein Barr Virus in Northern China
  203. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
  204. Protective and Predisposing HLA Alleles In Dutch Classical Hodgkin Lymphoma Patients
  205. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)
  206. Microenvironment, Cross-Talk, and Immune Escape Mechanisms
  207. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma
  208. Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
  209. Endoscopic detection of an early manifestation of EBV-related post-transplant lymphoproliferative disorder in a transplanted colon
  210. MHC class II as a therapeutic target in B-cell lymphomas: the CIITA road to paradise?
  211. Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin's Lymphoma Predicts Adverse Outcome in Older Adult Patients
  212. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes
  213. Beneath the Surface
  214. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
  215. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes
  216. HLA‐G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma
  217. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma
  218. HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma
  219. The Human Leukocyte Antigen Class I Region Is Associated with EBV-Positive Hodgkin's Lymphoma: HLA-A and HLA Complex Group 9 Are Putative Candidate Genes
  220. Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma
  221. A factorial experiment for optimizing the PCR conditions in routine genotyping
  222. Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region
  223. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma
  224. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma
  225. Immune Dysfunction in Classical Hodgkin’s Lymphoma
  226. High expression of B‐cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma
  227. Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma
  228. Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma
  229. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomas
  230. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues
  231. Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma
  232. Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy